Evidence map›Paper›PMID 41813724›Full record

Trial reportScientific reports2026

Return to work among self-employed breast cancer survivors from the CANTO cohort.

Chloé Lopez, Idlir Licaj, Agnès Dumas, Julie Havas, Antonio Di Meglio, Ines Vaz Luis, Barbara Pistilli, Fabrice André, Anne-Laure Martin, Dominique Delmas and 7 more

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01993498 (A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01993498 narecruitingnot on this map

A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer

TypeinterventionalSponsorUNICANCERRan2012 to 2034Enrolled14,750ConditionsBreast Cancer Nos Metastatic Recurrent, Early Lung CancerArmsblood sampling
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Chloé LopezUniversité Paris-Saclay, UVSQ, Gustave Roussy, Inserm, CESP, 94800, Villejuif, France.
Idlir LicajUniversité Paris-Saclay, UVSQ, Gustave Roussy, Inserm, CESP, 94800, Villejuif, France.
Agnès DumasSESSTIM (Economic and Social Sciences of Health and Medical Information Processing), INSERM, Aix Marseille Univ, IRD, ISSPAM, CALIPSO Team, Marseille, France.
Julie HavasUniversité Paris-Saclay, UVSQ, Gustave Roussy, Inserm, CESP, 94800, Villejuif, France.
Antonio Di MeglioUniversité Paris-Saclay, UVSQ, Gustave Roussy, Inserm, CESP, 94800, Villejuif, France.
Ines Vaz LuisUniversité Paris-Saclay, UVSQ, Gustave Roussy, Inserm, CESP, 94800, Villejuif, France.
Barbara PistilliMedical Oncology Department, Gustave Roussy, 94800, Villejuif, France.
Fabrice AndréUniversité Paris-Saclay, UVSQ, Gustave Roussy, Inserm, CESP, 94800, Villejuif, France.
Anne-Laure MartinData and Partnerships Department, Unicancer, Paris, France.
Dominique DelmasData and Partnerships Department, Unicancer, Paris, France.
Christelle JouannaudMedical Oncology Department, Institut Godinot, Reims, France.
Courèche KaderbhaiMedical Oncology Department, Centre Georges-François Leclerc, Dijon, France.
François CherifiMedical Oncology Department, Centre François Baclesse, Caen, France.
Mario CamponeMedical Oncology Department, Institut de Cancérologie de l'Ouest-Nantes, Saint-Herblain, France.
Marie-Ange Mouret-ReynierMedical Oncology Department, Centre Jean Perrin, Clermont-Ferrand, France.
Garazi Ruiz-de-AzuaUniversité Paris-Saclay, UVSQ, Gustave Roussy, Inserm, CESP, 94800, Villejuif, France. garazi.garazi-ruiz-de-azua@inserm.fr.ORCID http://orcid.org/0000-0002-7784-7571
Gwenn MenvielleUniversité Paris-Saclay, UVSQ, Gustave Roussy, Inserm, CESP, 94800, Villejuif, France.

Funding

Agence Nationale de la Recherche n°ANR-10-COHO-0004Fondation ARC pour la Recherche sur le Cancer PGA1 RF20170205420Institut National Du Cancer SHS-E-SP 2022-138
6 · The paper itself

Abstract

The aim of this study was to assess return to work (RTW) after breast cancer (BC) by baseline employment status. Using data from the CANTO cohort (NCT01993498), we examined RTW among women below age 57 at BC diagnosis 2 and 4 years after BC diagnosis. We also assessed continuous work between years 2 and 4 post-diagnosis. Poisson regression models investigated associations between baseline employment (self-employed vs. employees) and RTW outcomes, adjusting for clinical, sociodemographic, and work-related factors and quality of life. We used education (above high school; high school or lower) as a proxy to further distinguish between white collar self-employees vs. blue collar self-employees (vs. employees). About 8% of women were self-employed at diagnosis. RTW was slightly higher among the self-employed compared to employees 2 years (N = 3178; PR = 1.04, 95%CI 0.98–1.10) and 4 years after diagnosis (N = 2329; PR = 1.05, 0.99–1.12). This effect was limited to white collar self-employed women. Among those who returned to work 2 years after diagnosis (N = 1683), self-employed women showed a 1.15 (1.01–1.31) higher prevalence of continuous work until year 4 post-diagnosis than employees. Self-employed women do not strongly differ from employees when assessing RTW at specific time points, however once returned to work, they experience fewer work interruptions than employees. This was observed in adjusted models, showing the intrinsic importance of job status in the RTW process. These findings highlight the importance of viewing RTW as an ongoing process, in order to provide appropriate and sustained support.

Indexed as

Breast NeoplasmsCancer SurvivorsEmploymentReturn to WorkAdultCohort StudiesFemaleHumansMiddle AgedQuality of Life

Identifiers

PMID41813724
PMCPMC13103402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.